Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $91.72 in the prior trading day, Globus Medical Inc (NYSE: GMED) closed at $90.16, down -1.70%. In other words, the price has decreased by -$1.70 from its previous closing price. On the day, 1.59 million shares were traded. GMED stock price reached its highest trading level at $92.395 during the session, while it also had its lowest trading level at $88.6.
Ratios:
Our goal is to gain a better understanding of GMED by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 31.08 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.94. For the most recent quarter (mrq), Quick Ratio is recorded 2.47 and its Current Ratio is at 4.13. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On November 07, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $91.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 08 ’26 when Kline Kyle sold 3,594 shares for $101.10 per share. The transaction valued at 363,353 led to the insider holds 0 shares of the business.
Norwalk Leslie V sold 2,000 shares of GMED for $202,200 on Jan 08 ’26. The Director now owns 10,419 shares after completing the transaction at $101.10 per share. On Jan 08 ’26, another insider, Kline Kyle, who serves as the Officer of the company, bought 3,594 shares for $101.05 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 12176761856 and an Enterprise Value of 11796530176. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 29.14, and their Forward P/E ratio for the next fiscal year is 21.93. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.72. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.38 while its Price-to-Book (P/B) ratio in mrq is 2.76. Its current Enterprise Value per Revenue stands at 4.259 whereas that against EBITDA is 14.752.
Stock Price History:
The Beta on a monthly basis for GMED is 1.06, which has changed by 0.011803627 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, GMED has reached a high of $101.40, while it has fallen to a 52-week low of $51.79. The 50-Day Moving Average of the stock is 5.70%, while the 200-Day Moving Average is calculated to be 34.30%.
Shares Statistics:
The stock has traded on average 1.77M shares per day over the past 3-months and 1820220 shares per day over the last 10 days, according to various share statistics. A total of 112.18M shares are outstanding, with a floating share count of 111.36M. Insiders hold about 17.27% of the company’s shares, while institutions hold 88.22% stake in the company. Shares short for GMED as of 1767139200 were 4262628 with a Short Ratio of 2.41, compared to 1764288000 on 4397222. Therefore, it implies a Short% of Shares Outstanding of 4262628 and a Short% of Float of 4.29.
Earnings Estimates
At present, 12.0 analysts are actively evaluating the performance of Globus Medical Inc (GMED) in the stock market.The consensus estimate for the next quarter is $0.91, with high estimates of $0.97 and low estimates of $0.79.
Analysts are recommending an EPS of between $3.97 and $3.76 for the fiscal current year, implying an average EPS of $3.84. EPS for the following year is $4.19, with 12.0 analysts recommending between $4.4 and $3.85.
Revenue Estimates
11 analysts predict $793.69M in revenue. The current quarter. It ranges from a high estimate of $823.2M to a low estimate of $767.5M. As of. The current estimate, Globus Medical Inc’s year-ago sales were $657.29MFor the next quarter, 11 analysts are estimating revenue of $731.46M. There is a high estimate of $754.7M for the next quarter, whereas the lowest estimate is $698.93M.
A total of 12 analysts have provided revenue estimates for GMED’s current fiscal year. The highest revenue estimate was $2.94B, while the lowest revenue estimate was $2.88B, resulting in an average revenue estimate of $2.9B. In the same quarter a year ago, actual revenue was $2.52BBased on 12 analysts’ estimates, the company’s revenue will be $3.14B in the next fiscal year. The high estimate is $3.22B and the low estimate is $3.07B.
